Biologics CDMO (world's largest)
Samsung Biologics
The world's largest biologics CDMO, contract-manufacturing (CMO) drugs and developing cell lines and processes (CDO) for global pharma. It runs five Songdo plants totaling 785,000 liters; revenue is mostly from European (52%) and US (38%) customers. In 2025 it spun off Samsung Bioepis to become a pure-play CDMO.
207940.KS Updated Jul 11, 2026 4 AI consumers· 1 recurring
Per the valuechain.wiki graph, Samsung Biologics is directly linked to 3 companies (3 supply, 2 revenue relationships) and reaches 5 companies within two hops; the links are backed by 5 dated sources, 2 of them primary filings (as of 2026-07-11).
Financials & Segments
- Total revenue · Product (CMO) 95.6%, service (CDO) 4.4%; Europe 52%, US 38%, Korea 8.2%
- Segments · CMO manufacturing (785kL, 5 plants) · CDO development (cell line, process)
Revenue from
- 글로벌 빅파마 (CMO 위탁생산, 지역 익명) High confidence· Amount 2,074,700,000,000원 · 최대 CMO 계약(미국 제약사) · region-anonymized; $21.4B cumulative
Contract-manufactures biologics for global pharma; counterparties are region-only disclosed under confidentiality (with set reveal dates). 2024-25 megadeals: US pharma at KRW 2.07tn, 1.80tn and 1.46tn, an Asia pharma at KRW 1.70tn, a Europe pharma at KRW 0.93tn. Revenue split Europe 52%, US 38%. Cumulative orders ~$21.4B (112 CMO, 169 CDO).Confirms EN Reuters Published Jan 22, 2026: Samsung Biologics posts record CDMO orders, spins off Bioepis - 글로벌 빅파마 (CMO·CDO 위탁생산) High confidence· Amount $21.4B · 누적 수주 · 112 CMO, 169 CDO deals
The world's largest biologics CDMO (784,000L with plant 5 online): 112 CMO and 169 CDO cumulative deals worth $21.4B; record KRW 6.6tn of 2025 orders, guiding 15-20% revenue growth. - 리가켐바이오 (ADC 치료제 CDO 위탁개발) High confidence
Signed a CDO contract to develop LigaChem Biosciences' ADC therapeutic - a flagship CDO service engagement. - 리가켐바이오 (ADC CDO·CMO 수주) High confidence
Won ADC development and manufacturing mandates from LigaChem Biosciences (Feb 2024 CDO deal, Songdo ADC facility).Confirms KO Edaily Pharm Published Jun 17, 2024: Samsung Biologics deepens ADC CDMO tie-up with LigaChem
Pays to
- Samsung E&A Medium confidence
Samsung E&A built Songdo bio plants 1-5, the construction partner for capacity expansion. - 삼성E&A (송도 바이오플랜트 시공) Medium confidence
Samsung E&A (formerly Samsung Engineering) is the EPC partner building the Songdo plants 1-5 (785kL total). - 바이오프로세싱 원부자재 (배지·레진·필터, 싸이티바·써모피셔) Medium confidence
Sources bioprocessing consumables - cell-culture media, chromatography resins and single-use filters - from Danaher (Cytiva), Thermo Fisher and others for its CMO operations.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | lead2 | +11.4 | +6 | -8.6 | -4.8 | +47.5 | +25.6 |
| LigaChem Biosciences | lead1 | -26.2 | -18.1 | +37.1 | +151 | +60.5 | -40.7 |
| Samsung Biologics | node | -6.8 | +8.6 | +5.8 | +28.7 | +5 | -20.1 |
| Samsung E&A | benef1 | +74.5 | +20 | -13.7 | -15.9 | +76.7 | +43.2 |
| Danaher Corporation | benef1 | +48.6 | -19 | -1.2 | -0.3 | +0.4 | -12.7 |
| Ecopro HN | benef2 | · | +4.6 | +17 | -47.7 | +38 | -32 |
YTD as of 2026-07-10 · source: Yahoo Finance
Samsung Biologics operates across Biologics CDMO (world's largest). It is -20.1% in 2026. The supply side (avg +15.3%) has moved harder than the stock (-20.1%). That is the classic bottleneck pattern: supplier volume leverage is being priced before this layer's own margin. Among connected nodes the furthest ahead is Samsung E&A (+43.2%) and the furthest behind is LigaChem Biosciences (-40.7%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. In 2025 it spun off Samsung Bioepis to become a pure-play CDMO.
Analysis generated from returns as of 2026-07-10